SoFi shares rise as record revenue, member growth drive strong Q3 results
Kala Bio, Inc. (NASDAQ:KALA) Chief Financial Officer Mary Reumuth sold 33,197 shares of common stock on October 22 and 23, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock trades near its 52-week low of $1.1, having declined over 80% year-to-date. According to InvestingPro analysis, the company currently has a market capitalization of just $5.62 million. The sales, executed in two separate transactions, totaled $27,543.
On October 22, Reumuth sold 32,230 shares at a weighted average price of $0.83, with prices ranging from $0.82 to $0.84. The following day, October 23, she sold an additional 967 shares at $0.82 per share.
Following these transactions, Reumuth directly owns 28,906 shares of Kala Bio, Inc., which includes 28,906 unvested Restricted Stock Units. InvestingPro subscribers have access to 17 additional investment tips and comprehensive financial metrics for KALA, helping investors make more informed decisions about the company’s outlook.
In other recent news, Kala Bio, Inc. has faced significant challenges following the failure of its CHASE Phase 2b clinical trial for KPI-012, intended for the treatment of persistent corneal epithelial defect (PCED). The trial did not meet its primary endpoint, nor did it achieve statistical significance for key secondary efficacy endpoints, leading the company to halt the development of KPI-012 and its mesenchymal stem cell secretome platform. This development has prompted Mizuho analysts to anticipate continued weakness in Kala Bio’s stock. Additionally, the company received a default notice from Oxford Finance LLC, declaring a $29.1 million loan immediately due under their Loan and Security Agreement. The notice suggests that a material adverse change has occurred, with potential other defaults under the agreement. In a separate announcement, Kala Bio has scheduled its 2025 annual shareholder meeting for December 11, with further details to be disclosed in an upcoming proxy statement. These recent developments highlight a challenging period for Kala Bio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.